Companies: 10,795·Total market cap: $144.5T
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEMNASDAQHealthcare● Active
$13.25
$-0.26(-1.92%)
Market Cap$814318500
P/E Ratio
52W High$16.74
52W Low$5.68
Overview

Cullinan Therapeutics, Inc. (CGEM) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · CGEM · as of Jun 8, 2026

Activity summary

Buy transactions

8

P-Purchase only

Sell transactions

25

12 Months

Buy/Sell ratio

0.32

Buy/Sell (by trades)

Overall sentiment

BEARISH
↑ Buy 24%Active transactions only · RSU vesting excluded76% Sell ↓

Cullinan Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

CGEM insider buying and selling by quarter

CGEM insider selling · CGEM insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling
1.9M962K0
2025 Q3
2025 Q4
2026 Q1
2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · CGEM ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

CGEM executive sell shares · CGEM board member insider trading · CGEM insider trading SEC filing

Showing 61 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Michaelson Jennifer

Chief Scientific Officer

Option

Date

May 5

Shares

4,000

Price

$4.30

Value

$17K

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Sale

Date

May 5

Shares

7,800

Price

$14.60

Value

$114K

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Sale

Date

May 5

Shares

200

Price

$15.58

Value

$3K

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Option

Date

Mar 5

Shares

4,000

Price

$4.30

Value

$17K

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Sale

Date

Mar 5

Shares

8,000

Price

$15.68

Value

$125K

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Sale

Date

Feb 25

Shares

1,780

Price

$14.14

Value

$25K

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Sale

Date

Feb 23

Shares

1,752

Price

$13.99

Value

$25K

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Sale

Date

Feb 24

Shares

3,601

Price

$14.47

Value

$52K

View Form 4 on SEC.gov

AHMED NADIM

President and CEO · Director

Sale

Date

Feb 24

Shares

13,515

Price

$14.47

Value

$196K

View Form 4 on SEC.gov

Jones Jeffrey Alan

Chief Medical Officer

Sale

Date

Feb 24

Shares

4,582

Price

$14.47

Value

$66K

View Form 4 on SEC.gov

SUMER JACQUELYN L

Chief Legal Officer

Sale

Date

Feb 24

Shares

3,601

Price

$14.47

Value

$52K

View Form 4 on SEC.gov

Jones Jeffrey Alan

Chief Medical Officer

Sale

Date

Feb 20

Shares

4,982

Price

$13.62

Value

$68K

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Option

Date

Feb 20

Shares

8,000

Price

$4.30

Value

$34K

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Sale

Date

Feb 20

Shares

8,000

Price

$14.30

Value

$114K

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Sale

Date

Feb 20

Shares

3,742

Price

$13.62

Value

$51K

View Form 4 on SEC.gov

SUMER JACQUELYN L

Chief Legal Officer

Sale

Date

Feb 20

Shares

3,742

Price

$13.62

Value

$51K

View Form 4 on SEC.gov

AHMED NADIM

President and CEO · Director

Sale

Date

Feb 20

Shares

16,381

Price

$13.62

Value

$223K

View Form 4 on SEC.gov

Fenton Mary Kay

CFO

Sale

Date

Feb 20

Shares

4,398

Price

$13.62

Value

$60K

View Form 4 on SEC.gov

Fenton Mary Kay

CFO

Award

Date

Feb 18

Shares

68,750

Price

Value

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Award

Date

Feb 18

Shares

57,500

Price

Value

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Sale

Date

Feb 12

Shares

416

Price

$12.03

Value

$5K

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Sale

Date

Jan 22

Shares

4,000

Price

$12.30

Value

$49K

View Form 4 on SEC.gov

Fenton Mary Kay

CFO

Award

Date

Dec 31

Shares

27

Price

$6.49

Value

$175

View Form 4 on SEC.gov

AHMED NADIM

President and CEO · Director

Sale

Date

Dec 23

Shares

9,922

Price

$10.01

Value

$99K

View Form 4 on SEC.gov

Michaelson Jennifer

Chief Scientific Officer

Sale

Date

Dec 19

Shares

1,345

Price

$10.01

Value

$13K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About CGEM insider trading

CGEM insider trades

Cullinan Therapeutics, Inc. (CGEM) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Michaelson Jennifer (Chief Scientific Officer), Lynx1 Capital Management LP (10 percent owner), AHMED NADIM (President and CEO · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. CGEM insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Cullinan Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic
acquisitionOrDisposition field:
A = Acquisition (buy) · D = Disposition (sell)
RSU vesting (M-Exempt) excluded from sentiment
Form 4SEC filing required within 2 business days of any insider transaction
10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot
Open MktDirect purchase or sale on the open market (excludes awards, options)

Frequently asked questions

CGEM insider trading · 5 questions

The insiders of Cullinan Therapeutics, Inc. (CGEM) include executives and directors such as Michaelson Jennifer (Chief Scientific Officer), Lynx1 Capital Management LP (10 percent owner), AHMED NADIM (President and CEO · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

CGEM board member insider tradingwho are CGEM insidersCGEM insider rosterCullinan Therapeutics, Inc. executives insider activity

Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026